News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Optune trials opens for adult patients with low grade gliomas and pediatric patients with high grade gliomas


Posted on: 10/25/2017

1. Optune trial opens for patients with low grade gliomas

A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

 This trial will compare the use of Optune alone against the use of Optune combined with Temodar,  in patients with low grade gliomas.   

The Temodar will be using a metronomic  schedule (daily low dose instead of 5 days of high dose per month)  for 1 year. Optune will be used in both arms for 1 year.

2. Optune trial opens for pediatric patients with high grade gliomas!  This is a trial of the Optune NovoTTF-200A System With and Without Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Gliomas

 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites